🇺🇸 Treosulfane in United States
6 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 6
Most-reported reactions
- Acute Graft Versus Host Disease In Skin — 1 report (16.67%)
- Atypical Pneumonia — 1 report (16.67%)
- Bone Infarction — 1 report (16.67%)
- Osteomyelitis Fungal — 1 report (16.67%)
- Respiratory Failure — 1 report (16.67%)
- Zygomycosis — 1 report (16.67%)
Other Other approved in United States
Frequently asked questions
Is Treosulfane approved in United States?
Treosulfane does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Treosulfane in United States?
Novartis Pharmaceuticals is the originator. The local marketing authorisation holder may differ — check the official source linked above.